Back to top

Analyst Blog

Zacks Equity Research

DeVry Offers New Nursing Courses

APOL DV

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

DeVry, Inc. (DV - Analyst Report) recently launched graduate certificate programs in nursing education and nursing informatics under its Chamberlain College of Nursing. The introduction of the courses is in response to the growing demand for certified nurses. Applications are being accepted for the spring semester starting from January 2013.

The duration of the Graduate Certificate in Nursing Education is 12 to 15 semester credit hours and Nursing Informatics is 9 to 15 credit hours. The courses may include one or two 100-hour education practicum. The courses focus on competencies required to take major nursing examinations.

These courses have been designed to upgrade the skills of nurse educators and practicing nurses. The students can also opt for online courses with or without the practicum. The nurses are trained to use latest technology so that they can function in highly digitized healthcare settings.

DeVry witnessed solid new enrollment growth in Chamberlain College of Nursing and in other institutions like Carrington Colleges in the first quarter of 2013, owing to strong demand for medical courses. Total enrollments increased 20.2% at the Chamberlain College of Nursing and 2.1% at DeVry Medical International. Medical and Healthcare segment revenue grew 7.4% year over year in the quarter, driven by solid new enrollment growth.

DeVry, a peer of Apollo Group Inc.(APOL - Analyst Report), carries a Zacks #2 Rank in the near term (Buy rating). Continued progress on its performance improvement plan to align costs, regain enrollment growth and make growth investments, helped the company to deliver better-than-expected results in the first quarter fiscal 2013. The first quarter results were a turnaround from the past few weak quarterly results, thus justifying the short-term buy rating.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.38 +14.99%
ATLAS FINANC AFH 14.65 +2.85%
ZIOPHARM ONC ZIOP 3.44 +2.08%
ALLIANCE FIB AFOP 17.66 +1.96%
FEDERATED NA FNHC 20.26 +1.96%